Meta AnalysisID 6379
麝香保心丸治疗稳定型冠状动脉疾病的疗效与安全性：系统评价与Meta分析
CRD42022334529
The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6379
- Evidence Id
- 14937
- Core Evidence Id
- 14937
- Source Meta Analysis Id
- 6362
- Herb2 Meta Analysis Id
- HBMA006362
- Crd Id
- CRD42022334529
- Title
- Efficacy and Safety of Shexiang Baoxin Pill for Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis
- Review Question
- The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease.
- Study Type Included
- The randomized controlled trials (RCTs) which compared the effects of conventional treatment to conventional treatment combined with Shexiang Baoxin Pill on stable coronary artery disease will be included in this review.
- Condition Being Studied
- Cardiovascular diseases (CVDs) are the leading causes of death in many countries, accounting for 31.5% of deaths worldwide and 45% of all deaths due to non-communicable diseases. The combined use of aspirin and statin is a standard (and effective) secondary prevention approach to reduce the risk of cardiovascular events in patients with stable coronary artery disease (CAD). Nevertheless, some residual cardiovascular risks persist. Moreover, many patients with CAD in China, particularly females, are intolerant to aspirin because of gastrointestinal reactions, exacerbated respiratory disease, gout, or hyperuricemia. Therefore, novel approaches are urgently needed to reduce the residual CAD risk and as eventual alternatives for patients with intolerance to standard drugs. Traditional Chinese medicine (TCM) may be a potential add-on treatment and has long been used for treating CAD, which is considered as heart Yang deficiency resulting from Qi inadequacy. Shexiang Baoxin Pill（SBP） has been used to treat CAD and angina for more than 35 years in China. SBP is composed of bioactive components, including muscone, ginsenosides, storax, bufadienolides, cinnamic acid, arenobufagin, and borneol. Preliminary studies have indicated that SBP dilates coronary arteries and increases coronary blood flow, relieving the symptoms of angina.
- Participant
- RCTs of Shexiang Baoxin Pill for patients with stable coronary artery disease were strictly included and were not restricted by the publishing language. Specific and accurate data can be obtained for analysis. All subjects meet the relevant diagnostic criteria for stable coronary artery disease established by the American Heart Association or the Chinese Medical Association. Regardless of age, gender, race, and region. Exclusion Criteria. The research that is not rigorous, the data that is incomplete or has a significant error, and the statistical analysis that cannot be performed were excluded. The study on the treatment group or control group with other Chinese herbal medicine, the animal experiments, experience reports, conference papers, and the repeated published literature which could not get the full text were excluded.
- Animal
- Human Disease Modelled
- Intervention
- The intervention group received conventional treatment combined with Shexiang Baoxin Pill (produced by Shanghai He Huang Pharmaceutical Co., Ltd., oral administration, 22.5-45mg at a time, three times a day).
- Comparator Control
- The control group received conventional treatment including antiplatelet aggregation drugs, calcium channel blockers，β-receptor blockers, angiotensin-converting enzyme inhibitors, statins, nitrates, and nicorandil.
- Main Outcome
- Duration of angina symptoms, ECG improvement, adverse reactions. Measures of effect The relative risk (RR) was used for the effect measure of main outcomes.
- Outcome Measure
- Additional Outcome
- Blood lipid index includes total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) Measures of effect The mean difference (MD) was used for the effect measure of additional outcomes.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Coronary Artery Disease; Drugs, Chinese Herbal; Humans; shexiang baoxin
- Contact
- Jingjing Wei [email protected]
- Organisational Affiliation
- Henan University of Traditional Chinese Medicine www.hnzhy.com
- Funding Source
- This study was supported by the Ministry of Science and Technology of the People’s Republic of China’s Key Projects during the 13th Five-Year Plan Period (no.#2019YFC1710003) and the Chinese Medicine Evidence-Based Capacity Building Project of the State Administration of Traditional Chinese Medicine (2019XZZX-XXG003).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-05-22
- Registration Date
- 2022-06-03
- Anticipated Start Date
- 2022-05-23
- Anticipated Completion Date
- 2022-07-01
- Title Cn
- 麝香保心丸治疗稳定型冠状动脉疾病的疗效与安全性：系统评价与Meta分析
- Title En
- Efficacy and Safety of Shexiang Baoxin Pill for Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis
- Bilingual Status
- complete